Post Doctoral Training Fellow - Structural Biology & DNA Repair

04/07/2021, 23:55

Structural Biology
Struct Biol DNA repair
Part Time
Fixed Term
3 Years
£32,844 - £38,607
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

The ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top five cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

We are looking for a talented and enthusiastic post-doctoral training fellow to join the laboratory of Dr. Basil Greber in the Division of Structural Biology at the Institute of Cancer Research (ICR), based in central London. The position will be available immediately, but we also encourage candidates who have just received their degree (or will receive it in the next few months) to apply. 

The mechanisms by which cells preserve the integrity of their genomes are critical to our understanding of cancer biology and are a focus of several research groups at the ICR. Dr. Greber’s team at the ICR has been established recently and seeks a post-doctoral research scientist to develop an innovative and multidisciplinary research project to investigate the molecular mechanisms of nucleotide excision repair by combining cryo-electron microscopy (cryo-EM) with biochemical and biophysical methods. Dr. Greber’s previous contributions to the field of nucleotide excision repair include the determination of the complete structure of the human transcription factor IIH (Greber et al., Nature 549, 2017; Greber et al., eLife 8, 2019; Greber et al., PNAS 117, 2020), the centrepiece of this pathway. 

We provide a supportive environment and have established collaborations with expert groups within the ICR, in London, and internationally. Successful candidates should enjoy interacting and working with the principal investigator, other team members, and collaborators. 

Applicants should possess a PhD in molecular biology, biochemistry, biophysics, or a related discipline. Prior expertise in structural biology or cryo-EM is beneficial but not essential, and we would like to encourage candidates with in-depth experience in the biochemistry of nucleic acid-protein complexes and an interest in developing structural biology skills to apply. Additionally, we expect that the successful candidate has a track record of scientific excellence documented in authorship on published papers (which may include pre-prints).

We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.

The ICR is the leading academic research centre in the UK. Effective industry collaboration and innovation in new medicines and technologies are at the heart of our approach to drive benefits for patients. The ICR is ranked:


  • first for the quality and impact of our research*
  • second worldwide for the number of our publications cited in patents**
  • fourth worldwide for the citation rate of scientific research published across all fields**
  • fourth worldwide for top-cited research publications**
  • in the top five higher education institutions worldwide for academic influence and commercial impact**


*2014 Research Excellence Framework

** U-Multirank, 2020

Funded by

MRC - Medical Research Council
Additional Documentation for Candidates

This Program is closed to applications.